A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed.
The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.
A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed.
The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.
Location: United States, California, Agoura Hills
Employees: 51-200
Total raised: $208.5M
Founded date: 2018
Investors 1
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.01.2025 | Series C | $80M | - |
| 06.10.2020 | Series B | $71.5M | - |
| 05.11.2019 | Series A | $57M | - |
Mentions in press and media 10
| Date | Title | Description |
| 09.01.2025 | A2 Biotherapeutics Raises $80M Series C Funding | A2 Biotherapeutics, an Agoura Hills, CA-based clinical-stage cell therapy company developing logic-gated cell therapies to selectively target tumor cells and protect normal cells, raised $80M in Series C funding. Backers included The Column... |
| 23.12.2020 | A2 Biotherapeutics Enters Into Collaboration Agreement With Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers | Deal enables A2 to build allogeneic capability AGOURA HILLS, Calif.–(BUSINESS WIRE)–December 23, 2020– A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, t... |
| 23.12.2020 | A2 Biotherapeutics Enters Into Collaboration Agreement With Merck To Develop Allogeneic Cell Therapy For Solid Tumor Cancers | |
| 23.12.2020 | News briefing: Merck buys into A2's T cell therapy platform; Small Soligenix reports PhIII fail in head and neck cancer | Merck is dipping its toes into a cell therapy partnership with A2 Biotherapeutics, with an offer to co-fund clinical development and allogeneic manufacturing activities through Phase I. In particular, the phar... |
| 07.10.2020 | A2 Biotherapeutics Closes $71.5M Series B Funding | A2 Biotherapeutics, a Agoura Hills, Calif.-based biotechnology company developing innovative cell therapies for solid tumor cancer patients, closed its $71.5M Series B financing. Investors in the Series B include The Column Group, Vida Vent... |
| 06.10.2020 | A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of Its Potentially Transformative Selective Tumor Cell Therapeutics | AGOURA HILLS, Calif.–(BUSINESS WIRE)–October 6, 2020– A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for solid tumor cancer patients, today announced the closing of its $71.5M Series B finan... |
| 06.10.2020 | A2 Biotherapeutics Closes $71.5M Series B To Begin Clinical Development Of Its Potentially Transformative Selective Tumor Cell Therapeutics | |
| 06.11.2019 | A2 Biotherapeutics, Founded By Amgen Vets, Gets $57M For Cell Therapies | Agoura Hills-based A2 Biotherapeutics, a biotechnology firm started by veterans of Amgen which is developing cell therapies for cancer patients, has raised $57M in a Series A funding round, the company said this week. The startup was founde... |
| 05.11.2019 | A2 Biotherapeutics Raises $57M in Series A Funding | A2 Biotherapeutics, an Agoura Hills, Calif.-based biotechnology company developing innovative cell therapies for cancer patients, raised $57m in Series A funding. Backers included The Column Group, Vida Ventures, Samsara BioCapital and Next... |
| 05.11.2019 | A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A to Develop a Pipeline of Selective Tumor Cell Therapeutics | AGOURA HILLS, Calif.–(BUSINESS WIRE)–November 5, 2019– A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for cancer patients, today announced its official launch. The company, founded in 2018 b... |